Company
Thalia Therapeutics plc
LON:N4P
Thalia Therapeutics is a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The company is focused on unlocking the full therapeutic potential of RNA by overcoming the fundamental challenges of delivery, enabling targeted, scalable and clinically meaningful medicines for patients with significant unmet medical needs.
42 stories · page 1 of 3
Archive
Mobile Streams higher after launch of Pumas football club NFTs
A look at the major movers on the London market on Tuesday
Archive
Tintra climbs after short but dramatic update
A look at the major movers on the London market on Friday
Archive
Fevertree shares bubble up after rise in off-trade sales during lockdown
A look at the major movers on the London market on Thursday
Archive
Dillistone's solid start to the year blown off course
A look at some of the major movers in London on Thursday
N4 Pharma builds understanding of Nuvec as it looks towards clinical trials
Lab work in both in vitro and in vivo studies and an oncology efficacy model will be the next steps.
TechFinancials shares push higher after launch of blockchain diamond exchange
A look at some winners and losers in the UK equity market on Wednesday
N4 Pharma surges as MedImmune agrees to extend collaboration deal
The two parties had been working together as part of a project funded by the UK government and they have agreed to continue their research